A total of 143 patients had paired CD8 evaluations in the tumor center (CD8/CNT); among these, CD8/CNT increased significantly among all patients and all three trial arms separately (all p < 0.001, Wilcoxon test). The gene discussed is CD8A; the disease is neoplasm.